← All indications
Frailty
A state of increased vulnerability to stressors, following declines in function and reserves across multiple physiologic systems, characterized by MUSCLE WEAKNESS; FATIGUE; slowed motor performance; low physical activity; and unintentional weight loss.
Drugs by status
Phase 4 trials (9)
Phase 3 trials (1)
Phase 2 trials (23)
- sodium nitrite
- clazakizumab
- somatropin
- bone marrow derived mesenchymal stem cells
- vitamin c
- tesamorelin
- sitagliptin
- temozolomide
- dasatinib
- cellulose
- nicotinamide
- allogeneic adipose derived mesenchymal stem cell
- umbilical cord mesenchymal stem cells
- autologous bone marrow derived mesenchymal cells
- l-epigallocatechin
- sargramostim
- chlorhexidine
- quercetin
- ubiquinone
- fisetin
- isomyosamine
- ghrelin
- red job's tear
Phase 1 trials (6)
Organizations
Organization Involved with Phase 4 Indications (10)
Organization Involved with Phase 3 Indications (14)
Organization Involved with Phase 2 Indications (20)
- Millennium Pharmaceuticals
- Longeveron LLC
- The EMMES Corporation
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Huazhong University of Science and Technology
- University of Pennsylvania
- University of Pittsburgh
- University of Washington
- Indiana University
- Stanford University
- University of Miami
- University of Southern California
- University of Birmingham
- Mayo Clinic
- Capital Medical University
- Groupe Oncologie Radiotherapie Tete et Cou
- South Florida Bone Marrow/Stem Cell Transplant Institute
- Janssen Pharmaceutica NV
- University of Texas, San Antonio
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (7)